Home / Guides / Medicare and
Medicare’s $50
Medicare GLP-1 coverage in 2026: who qualifies for the $50 Bridge, and what if you don’t
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Through December 31, 2027, Medicare’s
- Covered: Wegovy pen or pill, Foundayo, the Zepbound KwikPen
- BMI: 35, or 30 or 27 with listed conditions
- Not counted: toward your deductible or $2,100 out-of-pocket cap
With Medicare, you can still pay yourself
NexLife’s providers prescribe compounded medicines only, not Zepbound or Wegovy, and NexLife doesn’t bill Medicare or other insurance.
Real people answer 24/7. Physicians answer medical questions during clinical hours.
4.8 out of 5 on Trustpilot, 407 reviewsLegitScript-certified
Compounded tirzepatide and semaglutide aren’t FDA-approved, and Medicare doesn’t cover them. With Medicare, you can still use NexLife and pay the monthly price yourself.
Medicare at a glance
| Question | Answer |
|---|---|
| What’s covered? | Wegovy (pen or pill), Foundayo and the Zepbound KwikPen, through Medicare’s |
| What does it cost? | $50 a month, from July 1, 2026 to December 31, 2027 |
| Who qualifies? | Part D enrollees with a BMI of at least 35, or 30 or 27 with listed conditions, when they started a |
| How do you get it? | Your prescriber requests prior authorization; a decision comes within 72 hours |
| What isn’t covered? | Zepbound vials and single-dose pens, KwikPen needles, and compounded tirzepatide or semaglutide |
| Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver? | The Bridge isn’t for you, but your Part D plan may cover a |
From Medicare.gov and CMS, read November 1, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Medicare’s
GLP-1 coverage for weight loss is the Bridge: $50 a month through 2027, if you qualify (checked November 1, 2026). - Covered: Wegovy (pen or pill), Foundayo and the Zepbound KwikPen, not Zepbound vials or compounded drugs.
- Who qualifies: Part D enrollees whose BMI was at least 35, or 30 or 27 with listed conditions, when starting a
GLP-1. - Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease? Your Part D plan may cover a
GLP-1 instead. - You don’t apply yourself: your prescriber requests prior authorization, and a decision comes within 72 hours.
- With Medicare, you can still pay yourself: compounded tirzepatide at NexLife, not FDA-approved, is $139 a month on the 12-month plan.
The Bridge
What is the Medicare GLP-1 Bridge?
A short-term CMS program that charges $50 a month for three brand-name GLP-1s: Wegovy (pen or pill), Foundayo and the Zepbound KwikPen. It runs from July 1, 2026 to December 31, 2027. It’s for people with Part D who meet its BMI and health rules, and it sits outside their Part D plan.
“The Medicare
GLP-1 Bridge is a short-term demonstration run by CMS that will provide eligible Medicare Part D beneficiaries with access to certainGLP-1 drugs between July 1, 2026, and December 31, 2027.”
- $50a month, for a one-month supplyWhatever your income
- 3.8 millionpeople with Part D met all its criteria in 2023KFF estimate
- 72 hoursfor a decision once your prescriber appliesCMS
| Who runs it | CMS, as a short-term demonstration that runs outside your Part D plan |
|---|---|
| Dates | July 1, 2026 to December 31, 2027 |
| Your cost | $50 for a one-month supply (28 or 30 days, by drug), whatever your income |
| Who can use it | People 18 or older with Medicare drug coverage (Part D) who meet its BMI and health criteria |
| Approval | Prior authorization from your prescriber, good through December 31, 2027 unless you change |
Which GLP-1s does the Bridge cover?
Wegovy (pen or pill) and Foundayo at every strength, including Wegovy HD 7.2 mg, and the Zepbound KwikPen, whose pen needles you buy separately. Foundayo was added on April 6, 2026. Zepbound vials, single-dose pens and compounded tirzepatide or semaglutide aren’t covered.
| Medicine | Under the Bridge |
|---|---|
| Wegovy pensemaglutide, weekly shot | Covered at every strength, including Wegovy HD 7.2 mg |
| Wegovy pillsemaglutide, daily | Covered at every strength |
| Foundayoorforglipron, daily pill | Covered at every strength (added April 6, 2026) |
| Zepbound KwikPentirzepatide, weekly; one pen holds 4 doses | Covered. Pen needles aren’t: you buy them separately |
| Zepbound vials or single-dose pens | Not covered |
| Compounded tirzepatide or semaglutide | Not covered |
Swipe the table sideways to see every column.
From Medicare.gov and CMS’s information for providers, read November 1, 2026. CMS says the list may change during the program.
Do you qualify?
Do you qualify for the Medicare GLP-1 Bridge?
You may, if you’re 18 or older with Part D. Your BMI must have been 35 or more when you started a
1. Do you have Medicare drug coverage (Part D)?
2. Does your Part D plan already pay for a
3. Do you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease?
4. Your height, and your weight when you started a
5. Any of these? Tap all that apply.
Answer the questions to see where you stand.
Built from Medicare.gov’s and CMS’s criteria, read November 1, 2026. Your prescriber’s prior authorization request decides.
The BMI rules
| If your BMI was | You also need one of these |
|---|---|
| 35 or more | Nothing more: BMI alone qualifies |
| 30 or more | Heart failure with preserved ejection fraction, uncontrolled high blood pressure (above 140/90 despite two blood pressure medicines) or chronic kidney disease stage 3a or higher, or a condition in the next row |
| 27 or more | Prediabetes, a past heart attack or stroke, or peripheral artery disease with symptoms |
Swipe the table sideways to see every column.
The Bridge’s criteria, from Medicare.gov and CMS, read November 1, 2026. You must be 18 or older. The BMI is the one you had when you started
Already on a
Who isn’t eligible for the Bridge?
Four groups can’t use it, CMS says. One is people whose Part D plan already pays for a GLP-1. Another is people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. The other two have no standalone Medicare drug plan, or no Medicare drug coverage at all. Here’s each one, and what to do instead:
- Your Part D plan already pays for a
GLP-1 for you, for any reason. You keep getting it through your plan. - You have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease (MASH). Your Part D plan may cover a
GLP-1 instead. - Your only Medicare coverage is a private fee-for-service plan, a cost plan or PACE, without a standalone drug plan.
- You have no Medicare drug coverage at all. You can join a drug plan only at certain times of the year.
How to apply
How do you apply, and how long does it take?
You don’t apply yourself: your prescriber and pharmacy do. The pharmacy asks your prescriber for prior authorization, typically within 24 to 72 hours, and the decision comes within 72 hours of the request, CMS says. Once approved, you pay $50 a month, and refills on the same drug need no new approval through December 31, 2027.
Talk with your prescriber
They check that a
GLP-1 fits you and that you meet the criteria. They also certify that you’re following a diet and exercise plan. They don’t need to be enrolled in Medicare, but they can’t be on Medicare’s preclusion list.The prescription goes to your pharmacy
The pharmacy may ask for your Medicare number, or the last 4 digits of your Social Security number. Then it sends the claim to the Bridge.
The pharmacy asks for prior authorization
It sends the request to your prescriber, typically within 24 to 72 hours. Your prescriber submits it online through CoverMyMeds or by fax.
A decision within 72 hours
It’s mailed to you and sent to your prescriber. If you’re approved, Medicare also sends you a letter.
Pay $50 at the pharmacy
Refills don’t need a new approval while you stay on the same drug, even if your dose changes. The approval lasts through December 31, 2027 unless you change
GLP-1s.
Denied? The Bridge has no appeals process. Your prescriber can send the form again with corrected or new information. To ask about your eligibility or the status of a request, call 1-800-MEDICARE (1-800-633-4227).
What $50 covers
What does the $50 cover, and what doesn’t it?
It covers a one-month supply of Wegovy, Foundayo or the Zepbound KwikPen for $50, whatever your income, with no deductible first. It doesn’t count toward your Part D deductible or the $2,100 out-of-pocket cap ($2,400 in 2027), Extra Help doesn’t lower it, and KwikPen needles aren’t covered.
It gets you
- A one-month supply of Wegovy, Foundayo or the Zepbound KwikPen
- The same $50 every month, whatever your income and whatever phase of Part D you’re in
- No deductible to meet first: you pay $50 from the first fill
- Refills and dose changes on the same drug, without a new approval
It doesn’t
- Count toward your Part D deductible or the $2,100 out-of-pocket cap ($2,400 in 2027)
- Get lower with Extra Help, Medicare’s program for people with limited income
- Spread out through the Medicare Prescription Payment Plan
- Cover pen needles for the KwikPen, or Zepbound vials and single-dose pens
Part D route
Does Medicare cover GLP-1s for diabetes, sleep apnea or fatty liver disease?
Then the Bridge isn’t for you, but your Part D plan can cover a
Type 2 diabetes
GLP-1 diabetes medicines such as Ozempic and Mounjaro go through your Part D plan’s list of covered drugs.Sleep apnea
Zepbound is approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
MASH
The Wegovy shot is approved for MASH, a fatty liver disease, with moderate to advanced scarring.
Heart disease
Wegovy is approved to lower the risk of heart attack, stroke and heart-related death in adults with heart disease and obesity or overweight.
Had a heart attack or stroke? You can still use the Bridge at a BMI of 27 if the prescription is for weight. If your prescriber writes Wegovy to lower your heart risk, it goes to your Part D plan instead, with your plan’s copay.
Not eligible?
Not eligible? What do GLP-1s cost without coverage?
You can pay cash at the makers’ self-pay prices (read November 1, 2026). At LillyDirect, Zepbound is $299 a month at 2.5 mg and $399 at 5 mg; from 7.5 mg it’s $449 with a refill within 45 days, or $499 to $699 if not. The Wegovy pen is $349 ($399 for Wegovy HD). The Wegovy pill is $149 to $299. Foundayo is $149 to $299 by dose; its 2.5 and 5.5 mg prices are reduced only through December 31, 2026, and 14.5 and 17.2 mg need a refill within 45 days. Cash purchases don’t count toward your Medicare deductible or out-of-pocket limit. Next year’s prices: Wegovy price in 2027.
| Medicine | Cash price a month | What to know |
|---|---|---|
| Zepbound KwikPen or vialsLillyDirect, self-pay | $299 to $449 | $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg with a refill within 45 days ($499 to $699 if not). Needles extra |
| Wegovy penNovoCare, self-pay | $349 | $399 for Wegovy HD 7.2 mg. New patients: $199 for two fills at 0.25 or 0.5 mg, through December 31, 2026 |
| Wegovy pillNovoCare, self-pay | $149 to $299 | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 or 25 mg |
| Foundayo pillLillyDirect, self-pay | $149 to $299 | By dose. The 2.5 and 5.5 mg prices are temporarily reduced through December 31, 2026; 14.5 and 17.2 mg need a refill within 45 days |
| Through the Bridgeif you qualify | $50 | Wegovy, Foundayo or the Zepbound KwikPen |
Swipe the table sideways to see every column.
Self-pay prices from LillyDirect and Novo Nordisk’s Wegovy site, read November 1, 2026: the medication alone, with your prescriber’s visit extra. A Zepbound month is 28 days.
Medicare.gov itself points people who don’t qualify to TrumpRx.gov to compare cash prices. You can’t buy drugs there, and cash purchases don’t count toward your Medicare deductible or out-of-pocket limit. Lilly’s self-pay terms also say you can’t bill those purchases to any insurance, Medicare included. More on paying yourself: Zepbound’s cash price, dose by dose.
Every program
How do all 14 compounded tirzepatide programs compare?
Medicare doesn’t cover compounded tirzepatide, which isn’t FDA-approved, so these are self-pay prices: every program in our price index, all in, checked November 1, 2026.
| Program | Month to month, all in | Longest plan, per month | Same price at every dose? |
|---|---|---|---|
| PreventiveMD | $139 | Prepaid 3 to 12 months, not in our index | Yes |
| NexLife (publisher of this guide) | $169 | $139 (12 months) | Yes |
| Mochi Health | $169 (at the lowest dose) | $139 (lowest dose, 12-month membership) | No, rises with dose |
| Ivím Health | $192 (at the lowest price listed) | Not published | Not stated |
| Alloy | $199 (at the lowest price listed) | Monthly only | Not stated |
| Ondra Health | $219 | $142 (12 months, $1,699 upfront) | Yes |
| Cora | $225 | $135 (12 months, $1,620 upfront) | Yes |
| Refills | $249 (shown against a struck-through $349) | $159 (12 months) | Yes |
| Rx.com | $285 | $149 (12 months, $1,788 upfront) | Yes |
| Noom | $299 (after a $149 first month) | Billed $897 every 12 weeks | Not stated |
| Raeliva | $299 | $242 (6 months, $1,450 upfront) | Yes |
| Shapely | $348 (low to mid dose; $398 high dose) | $265 (3-month starter package, with membership) | No, rises with dose |
| Embody | $349 (its regular price) | Prepaid bundles, not in our index | Yes |
| Remedy Meds | $399 (every 4 weeks, after $279 at first) | Month to month only | Yes |
All in means the medication plus any required membership or program fee. Each price links to the program’s own page, read November 1, 2026. Every program and its notes: our GLP-1 price index.
NexLife and Medicare
Can NexLife help if you have Medicare?
Yes, if you pay yourself. People with Medicare can use NexLife at the price every member pays. Compounded tirzepatide is $139 a month on the 12-month plan, or $169 month to month, and semaglutide $119 or $139, at every dose. NexLife doesn’t bill Medicare, and Medicare doesn’t cover compounded medicines.
The Bridge may cost you less. NexLife’s providers prescribe compounded medicines only, not brand-name Zepbound or Wegovy, so we can’t write a Bridge prescription. If you qualify for the Bridge, its $50 a month costs less than paying cash, ours included. The Price Match Guarantee† isn’t open to people with Medicare, Medicaid or TRICARE coverage.
HSA or FSA? NexLife provides a letter of medical necessity if your plan asks for one. Once you enroll in Medicare, you can’t add money to an HSA, but you can still spend what’s in it.
Questions first? Call or text
Check my eligibilityCompounded, not FDA-approved: a licensed provider prescribes it only when it offers a significant difference for you.
After 2027
What happens to the Bridge after 2027?
It’s set to end on December 31, 2027, and nothing is announced for 2028, as of November 1, 2026. CMS already extended it once; it was first planned to end in 2026. On April 21, 2026, CMS said its BALANCE Model wouldn’t start in Medicare in 2027. What else changes on January 1, 2027:
The Bridge is set to end. CMS extended it once already: it was first planned to run only through 2026.
Nothing is announced. On April 21, 2026, CMS said its longer program for Part D plans, the BALANCE Model, wouldn’t start in Medicare in 2027. KFF found no clear path for coverage after 2027.
Separate rules. In Medicaid, states that opt in can join BALANCE from May 2026 through January 1, 2027, CMS says. Thirteen state Medicaid programs covered
GLP-1s for obesity as of January 2026.
Two medications.
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included.
GIP + 12-month plan $139/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $169/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication
12-month plan $119/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
Medicare and GLP-1s: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Does Medicare cover compounded tirzepatide or semaglutide?
No. The Bridge covers only Wegovy, Foundayo and the Zepbound KwikPen. Outside it, the law bars Medicare drug plans from covering drugs used for weight loss. NexLife doesn’t bill Medicare, but people with Medicare can use NexLife and pay the monthly price themselves.
What are the best weight loss drugs covered by Medicare?
For weight loss alone, Medicare covers three, and only through its
Does Medicare cover Zepbound for weight loss in 2026?
Yes, but only the Zepbound KwikPen, through the Medicare
What is the Medicare GLP-1 Bridge?
A short-term CMS program that covers Wegovy, Foundayo and the Zepbound KwikPen for weight loss, for a $50 copay, from July 1, 2026 to December 31, 2027. It’s for people with Medicare drug coverage (Part D) who meet its criteria, and it runs outside their Part D plan.
Who qualifies for the $50 GLP-1 Bridge?
Adults with Part D whose BMI was 35 or more when they started a
What is the tirzepatide price for seniors?
Seniors with Part D who qualify pay $50 a month for the Zepbound KwikPen through the Bridge, until December 31, 2027. Otherwise, LillyDirect charges $299 to $449 a month (checked November 1, 2026); $449 needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide at NexLife, not FDA-approved, is $139 a month on the 12-month plan.
Can I get tirzepatide if I’m over 65?
Age alone doesn’t rule it out: Zepbound’s label reports no overall differences in safety or effectiveness between people 65 and older and younger adults. With Part D, the Bridge can cover the Zepbound KwikPen if you qualify. You can also pay yourself at NexLife, where a licensed provider decides whether compounded tirzepatide is right for you.
Does the $50 count toward my Part D out-of-pocket limit?
No. The Bridge runs outside your Part D plan, so the $50 doesn’t count toward your deductible or the $2,100 out-of-pocket cap ($2,400 in 2027). Extra Help doesn’t lower it, and the Medicare Prescription Payment Plan can’t spread it out. There’s no deductible to meet first: you pay $50 from the first fill.
How long does Bridge approval take?
The decision comes within 72 hours of your prescriber’s request, CMS says. First, after the pharmacy sends your claim, it asks your prescriber for prior authorization, typically within 24 to 72 hours. The decision is mailed to you and sent to your prescriber. Once you’re approved, refills on the same drug need no new approval.
What happens to the Bridge after 2027?
It’s set to end on December 31, 2027, and nothing is announced for 2028, as of November 1, 2026. CMS already extended it once: it was first planned to end in 2026. On April 21, 2026, CMS said the BALANCE Model, its longer program for Part D plans, won’t start in Medicare in 2027.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and checked this page
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Medicare’s and CMS’s rules and the makers’ prices checked November 1, 2026.
- How we checked. The Bridge’s rules come from Medicare.gov, Medicare’s fact sheet and CMS’s pages for patients and prescribers, read November 1, 2026. The BALANCE Model’s status comes from CMS, read the same day; out-of-pocket caps and the eligibility estimate come from KFF. Cash prices are each maker’s own self-pay prices, read November 1, 2026.
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
With Medicare, you can still pay yourself.
A real prescription. A fair price.
Start online in about 3 minutes. A licensed provider decides if treatment is right for you.
4.8 out of 5 on Trustpilot · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
Sources
- Medicare.gov: Weight loss drugs (the Medicare
GLP-1 Bridge). Read November 1, 2026. - Medicare.gov: Medicare
GLP-1 Bridge:GLP-1 drugs for $50 a month, fact sheet (CMS Product No. 12234, June 2026). Read November 1, 2026. - CMS: Medicare
GLP-1 Bridge, overview and FAQs. Read November 1, 2026. - CMS: Medicare
GLP-1 Bridge, information for providers. Read November 1, 2026. - CMS: Medicare
GLP-1 Bridge prior authorization request form. Read November 1, 2026. - CMS: BALANCE Model (page modified September 29, 2026). Read November 1, 2026.
- KFF: What to know about the BALANCE Model for
GLP-1s in Medicare and Medicaid and the MedicareGLP-1 Bridge (updated May 11, 2026). - KFF: Nearly four million Medicare beneficiaries met the eligibility criteria in 2023 for the Medicare
GLP-1 Bridge (June 29, 2026). - Eli Lilly: Zepbound through LillyDirect, self-pay prices. Read November 1, 2026.
- Eli Lilly: Foundayo through LillyDirect, self-pay prices. Read November 1, 2026.
- Novo Nordisk: Wegovy cost and coverage. Read November 1, 2026.
- Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 1, 2026.
- U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Read November 2, 2026.
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge. Information for Pharmacies. Read November 2, 2026.
- Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge. Information for Part D Plans. Read November 2, 2026.
- Medicare.gov. Help with drug costs. Read November 2, 2026.
- Medicare.gov. Joining a plan. Read November 2, 2026.